HC Wainwright Predicts Lower Earnings for Sage Therapeutics

Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Research analysts at HC Wainwright cut their FY2028 earnings per share (EPS) estimates for shares of Sage Therapeutics in a research report issued on Wednesday, October 30th. HC Wainwright analyst D. Tsao now forecasts that the biopharmaceutical company will post earnings of $0.50 per share for the year, down from their previous forecast of $0.56. HC Wainwright currently has a "Neutral" rating and a $14.00 target price on the stock. The consensus estimate for Sage Therapeutics' current full-year earnings is ($6.43) per share.

A number of other equities research analysts have also issued reports on SAGE. Bank of America dropped their target price on Sage Therapeutics from $11.00 to $6.00 and set an "underperform" rating on the stock in a research report on Wednesday, October 9th. TD Cowen cut shares of Sage Therapeutics from a "buy" rating to a "hold" rating and cut their price target for the stock from $16.00 to $10.00 in a research report on Tuesday, July 30th. Scotiabank decreased their price objective on Sage Therapeutics from $17.00 to $14.00 and set a "sector outperform" rating for the company in a report on Wednesday. JPMorgan Chase & Co. dropped their target price on Sage Therapeutics from $12.00 to $10.00 and set a "neutral" rating on the stock in a report on Tuesday, August 6th. Finally, Piper Sandler restated an "overweight" rating and issued a $26.00 price target (down from $52.00) on shares of Sage Therapeutics in a research note on Wednesday. Two analysts have rated the stock with a sell rating, eighteen have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $12.89.

Sage Therapeutics Trading Down 5.4 %

Shares of Sage Therapeutics stock traded down $0.35 during trading on Thursday, reaching $6.09. The stock had a trading volume of 1,111,237 shares, compared to its average volume of 978,423. The company has a market capitalization of $366.51 million, a price-to-earnings ratio of -0.74 and a beta of 0.91. The stock has a fifty day moving average price of $7.48 and a two-hundred day moving average price of $9.97. Sage Therapeutics has a 52 week low of $5.84 and a 52 week high of $28.26.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) EPS for the quarter, missing analysts' consensus estimates of ($1.52) by ($0.01). The company had revenue of $11.87 million for the quarter, compared to analyst estimates of $10.80 million. Sage Therapeutics had a negative return on equity of 55.87% and a negative net margin of 458.30%. The company's revenue was up 337.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($2.81) earnings per share.

Institutional Trading of Sage Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Harbor Capital Advisors Inc. increased its position in Sage Therapeutics by 21.7% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 45,738 shares of the biopharmaceutical company's stock worth $330,000 after purchasing an additional 8,166 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Sage Therapeutics by 66.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company's stock valued at $85,000 after acquiring an additional 4,672 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Sage Therapeutics by 11.3% during the third quarter. Assenagon Asset Management S.A. now owns 186,039 shares of the biopharmaceutical company's stock worth $1,343,000 after purchasing an additional 18,814 shares during the period. Creative Planning bought a new stake in shares of Sage Therapeutics in the third quarter worth $88,000. Finally, Inspire Investing LLC increased its holdings in Sage Therapeutics by 77.0% in the third quarter. Inspire Investing LLC now owns 57,772 shares of the biopharmaceutical company's stock valued at $417,000 after purchasing an additional 25,139 shares during the period. 99.22% of the stock is currently owned by institutional investors.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.